Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results

This is the authors' abstract. We don't add key points for this paper.

Low-dose, intermittent rapamycin administration over 48 weeks is relatively safe in healthy, normative-aging adults, and was associated with significant improvements in lean tissue mass and pain in women. Future work will evaluate benefits of a broader range of rapamycin doses on healthspan metrics for longevity, and will aim to more comprehensively establish efficacy.